Discover 1,672 paid clinical trials in Sandy Springs, Georgia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,672
Peanuts for Cardiometabolic, Brain, and Intestinal Health
for
Prediabetes,
Location: Atlanta GA
Sponsor: Georgia State University
Sex: All
Age: 20 - 59
Code: NCT06867198
Recruiting
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
for
Schizophrenia, Schizo-Affective Disorder,
Location: Decatur GA, Hialeah FL, DeSoto TX, Anaheim CA
Sponsor: BioXcel Therapeutics Inc
Sex: All
Age: 10 - 17
Code: NCT05025605
Phase 1, Recruiting
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
for
Advanced Lung Non-Small Cell Carcinoma,
Location: Atlanta GA
Sponsor: Emory University
Sex: All
Age: 18+
Code: NCT06731270
Phase 2, Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Location: Atlanta GA, Birmingham AL, Savannah GA, Lexington KY,
Sponsor: The University of Texas Health Science Center, Houston
Sex: All
Age: 0 - 1
Code: NCT05685745
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Location: Atlanta GA, Charlotte NC, Winston-Salem NC,
Sponsor: CellCentric Ltd.
Sex: All
Age: 18+
Code: NCT07096778
Phase 2, Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
for
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma,
Location: Atlanta GA, Birmingham AL, Durham NC, Indianapolis IN,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT07488676
Phase 1, Phase 2, Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)